← Back to all grants

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

Funding
Up to $1,500,000
Deadline
November 5, 2027
Who can apply
State governments, County governments, City or township governments +11 more
Status: Open
Source: Grants.gov
View Official Grant Page ↗
Add the deadline to your calendar:Download .icsGoogle Calendar

Description

The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public and state-controlled colleges and universities
  • Federally recognized Native American tribal governments
  • Public and Indian housing authorities
  • Other Native American tribal organizations
  • Nonprofits with 501(c)(3) status
  • Nonprofits without 501(c)(3) status
  • Private colleges and universities
  • For-profit organizations (other than small businesses)
  • Small businesses

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Industry Tags

Healthcare

About This Grant

The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.

Funding Information

Award Ceiling
$1,500,000

Eligibility Overview

Eligible applicants include: State governments, County governments, City or township governments +11 more. Always confirm on the official listing.

Eligibility requirements vary by opportunity. Always review the official listing before investing time in an application.

How to Apply

  1. 1

    Review the full opportunity

    Read the complete Notice of Funding Opportunity (NOFO) for this National Institutes of Health program on its official page (https://www.grants.gov/search-results-detail/357529).

  2. 2

    Confirm eligibility

    Check that your organization meets every requirement set by National Institutes of Health — applicant type, location, registration status, and any prior-award restrictions.

  3. 3

    Prepare required documents

    Gather your budget narrative, needs statement, organizational details, SAM.gov registration, and any required certifications.

  4. 4

    Submit before the deadline

    This opportunity closes on November 5, 2027. Submit well before the deadline to leave time for fixes.

Grant Writing Tips

General tips for preparing your application:

  • ✓Start early: registration and review steps take time.
  • ✓Match your needs statement to the funder's stated priorities.
  • ✓Have someone outside your team check the budget narrative.

More Grants from National Institutes of Health

Frequently Asked Questions

Who is eligible for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)?

Eligible applicants include: State governments, County governments, City or township governments +11 more. Always confirm on the official listing.

How much funding does Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) provide?

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) provides awards of up to $1,500,000.

When is the deadline for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)?

The application deadline for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) is November 5, 2027. Submit well before the deadline to leave time for fixes.

How do I apply for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)?

Apply for Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) through the official grant page (https://www.grants.gov/search-results-detail/357529). Confirm your eligibility and prepare your application materials before the deadline.

Helpful Resources

✍️Grant Writing Help

Need help writing your grant application?

Try Instrumentl — Grant Writing Software →
🏢Start Your Business

Need to form an LLC or corporation first?

Form your business with ZenBusiness →
🤝Nonprofit Formation

Starting a nonprofit to apply for grants?

Launch your nonprofit with Swyft Filings →
📊Grant Management

Track and manage multiple grant applications?

Try Bloomerang for nonprofits →

GrantLocate may earn a commission from qualifying purchases. This does not affect our grant listings.

Related Grants